UnitedHealth Group Incorporated (UNH)

Return on equity (ROE)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	14,405,000	14,317,000	14,103,000	15,361,000	22,381,000	21,687,000	21,108,000	20,704,000	20,120,000	19,430,000	18,254,000	17,450,000	17,285,000	15,426,000	14,512,000	16,883,000	15,403,000	16,732,000	17,098,000	13,754,000
Total stockholders’ equity	US$ in thousands	92,658,000	99,881,000	84,801,000	86,688,000	88,756,000	84,494,000	82,353,000	81,312,000	77,772,000	74,646,000	72,820,000	72,766,000	71,760,000	70,278,000	69,014,000	66,404,000	65,491,000	65,231,000	63,624,000	56,977,000
ROE		15.55%	14.33%	16.63%	17.72%	25.22%	25.67%	25.63%	25.46%	25.87%	26.03%	25.07%	23.98%	24.09%	21.95%	21.03%	25.42%	23.52%	25.65%	26.87%	24.14%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $14,405,000K ÷ $92,658,000K
= 15.55%

UnitedHealth Group Incorporated's Return on Equity (ROE) has shown fluctuations over the past few years.

From March 31, 2020, to March 31, 2024, the ROE ranged from a high of 26.87% in June 2020 to a low of 14.33% in September 2024. This indicates that the company's ability to generate profit from its shareholder equity varied significantly during this period.

The ROE was generally above 20% in the initial years but experienced a decline towards the latter part of the period, falling to 15.55% by December 31, 2024, from the peak levels observed earlier.

The downward trend in ROE from mid-2023 to the end of 2024 suggests potential challenges that UnitedHealth Group may have faced in efficiently utilizing its equity to generate profits for its shareholders.

Further analysis of the company's financial performance and operational efficiency during this period would be needed to understand the factors driving these fluctuations in ROE and to assess the company's overall financial health and sustainability.

Overall, monitoring UnitedHealth Group's ROE along with other financial metrics would provide valuable insight into the company's profitability and efficiency in utilizing its equity capital.